Evaluation of side effects events peripheral neuropathy and lipodystrophy in patients with HIV/AIDS who used stavudine in antiretroviral regimens

Abstract Background The use of stavudine in antiretroviral regimens is often associated with undesirable effects such as peripheral neuropathy and lipodystrophy. This study aims to overview the prevalence of adverse events of peripheral neuropathy and lipodystrophy in HIV/AIDS patients who used stavudine in antiretroviral and factors that influence the incidence of side effects of stavudine. Materials and methods This study was a retrospective cohort study design. The intervention groups were patients who used stavudine and control groups were patients who used zidovudine. To determine the incidence of peripheral neuropathy used the Subjective Peripheral Neuropathy Screen (SPNS) and the incidence of lipodystrophy used Carr Lipodystrophy Questionnaire and patient's medical records retrospectively. Results The prevalence of peripheral neuropathy was 25.3% and lipodystrophy 40.9% in patients who used stavudine. Differences combination of antiretroviral regimen was factor that significantly influence the incidence of side effects of peripheral neuropathy ( p  = 0.002). Age ( p  = 0.039), duration of stavudine use ( p  = 0.000), previous antiretroviral regimen ( p  = 0.013) and differences combination of antiretroviral regimen ( p  = 0.000) were the factors most significantly influence the side effects of lipodystrophy. Stavudine likely to cause peripheral neuropathy compared zidovudine with relative risk (RR) = 3.039 (95% CI, 1629–5670) and odds ratio (OR) = 3.178 (95% CI, 1156–6660). Stavudine likely to cause lipodystrophy compared zidovudine with relative risk (RR = 1.488 (95% CI) and odds ratio (OR) = 3.353 (95% CI, 1876–5992). Conclusions The side effects of peripheral neuropathy and lipodystrophy at the use of antiretroviral regimens stavudine was significantly different from antiretroviral regimen zidovudine.

• Publication year

  2013

• Venue

  HIV and AIDS Review

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.HIVAR.2013.02.002
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen.

  2010cited by this paper
• An Analysis of Enzyme Kinetics Data for Mitochondrial DNA Strand Termination by Nucleoside Reverse Transcription Inhibitors

  2009cited by this paper
• Broadband Criticality of Human Brain Network Synchronization

  2009cited by this paper
• Stavudine plasma concentrations and lipoatrophy.

  2008cited by this paper
• Metabolic Function and the Prevalence of Lipodystrophy in a Population of HIV-Infected African Subjects Receiving Highly Active Antiretroviral Therapy

  2007cited by this paper
• High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.

  2007cited by this paper
• Adverse effects of highly active antiretroviral therapy in developing countries.

  2007cited by this paper
• Mitochondrial Toxicity of Nucleoside Analogues in Primary Human Lymphocytes

  2005cited by this paper
• The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.

  2004cited by this paper
• Adverse effects of antiretroviral therapy for HIV infection.

  2004cited by this paper
• Prevalence of Lipoatrophy and Mitochondrial DNA Content of Blood and Subcutaneous Fat in HIV-1-Infected Patients Randomly Allocated to Zidovudine- or Stavudine-Based Therapy

  2003cited by this paper
• Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact.

  2002cited by this paper
• Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy.

  2002cited by this paper
• Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

  2002cited by this paper
• Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: Effect of stavudine exposure and antiretroviral experience

  2002cited by this paper
• Psychosocial impact of the lipodystrophy syndrome in HIV infection.

  2000cited by this paper
• Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.

  1999cited by this paper

• No citing papers are available for this paper.